{"id":"W2773969925","doi":"10.1016/s2213-8587(17)30412-6","title":"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis","year":2017,"lang":"en","type":"review","venue":"The Lancet Diabetes & Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":592,"is_retracted":false,"has_abstract":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"AstraZeneca; National Heart, Lung, and Blood Institute; Amylin Pharmaceuticals","keywords":"Medicine; Semaglutide; Liraglutide; Lixisenatide; Exenatide; Glucagon-like peptide 1 receptor; Internal medicine; Type 2 diabetes; Placebo; Myocardial infarction; Dulaglutide; Meta-analysis; Adverse effect; Odds ratio; Stroke (engine); Hazard ratio; Diabetes mellitus; Agonist; Endocrinology; Receptor; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0007120169,0.001282993,0.01411814,0.0007729171,0.0002078071,0.0001289726,0.001153154,0.0002516696,0.0002337722],"category_scores_gemma":[0.0001102711,0.000605634,0.003593139,0.0009584652,0.0004623303,0.0001360484,0.0004082186,0.0007909512,0.0002718949],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002602698,"about_ca_system_score_gemma":0.0001732087,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005628795,"about_ca_topic_score_gemma":0.0001019888,"domain_scores_codex":[0.9941767,0.0005680486,0.0008390433,0.001278255,0.0007786137,0.002359367],"domain_scores_gemma":[0.9940426,0.0003712548,0.0007800676,0.004420499,0.0002083547,0.0001772486],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00006294604,0.0003916983,0.1489872,0.003159244,0.6926251,0.00006996507,0.00003652316,0.00001107607,2.711788e-8,0.00005398568,0.001124105,0.1534782],"study_design_scores_gemma":[0.001790973,0.000556257,0.01117585,0.0003843677,0.4011014,7.259871e-7,0.000004933142,8.570919e-7,8.171332e-7,0.000006325133,0.584545,0.0004325361],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.009185346,0.9849399,0.000001153647,0.0003984383,0.0002830507,0.003407278,0.0001408968,0.000154857,0.001489113],"genre_scores_gemma":[0.003490421,0.9874777,0.00047692,0.000816926,0.0002222298,0.002138108,0.001769373,0.0002182131,0.003390108],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.5834209,"threshold_uncertainty_score":0.9999922,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09996280311863774,"score_gpt":0.3291057581735825,"score_spread":0.2291429550549447,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}